British Pharmacopoeia at the JPAG Hot Topics Meeting
Published 12 December 2025
Earlier this month, Peter Crowley, Editor-in-Chief of the British Pharmacopoeia (BP), addressed the 10th annual Hot Topics meeting of the Joint Pharmaceutical Analysis Group (JPAG) at the Royal Society of Chemistry in London. His contribution formed part of a programme designed to help industry professionals understand emerging regulatory themes and the future direction of pharmaceutical standards.
As Editor-in-Chief, Peter is responsible for the strategic direction, scientific integrity and regulatory alignment of the BP. His work ensures the BP remains a trusted global reference source that supports compliant manufacturing and helps safeguard access to quality medicines for patients. Peter also represents the BP within the wider standards community, engaging directly with regulators, industry specialists and global pharmacopoeias to support harmonisation and innovation.
At the meeting, Peter outlined key developments in the BP 2026 edition, including forthcoming monograph updates, new supporting texts and the BP’s wider approach to future standards. He also highlighted work on sustainability, the role of artificial intelligence at the BP, and the introduction of non-mandatory guidance designed in collaboration with experts in innovative fields such as cell and gene therapy.
These updates form part of the BP’s commitment to supporting the pharmaceutical sector through clear, science-led standards and practical guidance. Our work helps the industry address emerging technologies, adapt to new regulatory expectations and maintain confidence in the quality of medicines supplied to patients.
Reflecting on the event, Peter said:
“The JPAG regulatory hot topics event consistently features engaging and varied discussions. This year’s programme included insightful updates on Modular Manufacture, presented by MHRA’s Quality Assessor, Elspeth Gray, and a dynamic discussion concerning the application of AI in pharmaceutical analysis and submission. It is always a privilege to attend.”
The BP will continue to work closely with all stakeholders to ensure that future editions sustain the development of standards and guidance for patient benefit with the scientific rigour needed to support a resilient and evolving medicines supply.
Visit the events section to see other training and events from BP - https://www.pharmacopoeia.com/news/the-bp/training-and-events